Last reviewed · How we verify

Chengdu Zenitar Biomedical Technology Co., Ltd — Portfolio Competitive Intelligence Brief

Chengdu Zenitar Biomedical Technology Co., Ltd pipeline: 0 marketed, 0 filed, 2 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 4 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Purinostat Mesylate for Injection Purinostat Mesylate for Injection phase 3 Histone deacetylase inhibitor Histone deacetylases Oncology
Selinexor Tablets Selinexor Tablets phase 3 Selective inhibitor of nuclear export (SINE) XPO1/CRM1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Jiangsu HengRui Medicine Co., Ltd. · 2 shared drug classes
  2. Astex Pharmaceuticals, Inc. · 1 shared drug class
  3. Celgene · 1 shared drug class
  4. Centre Leon Berard · 1 shared drug class
  5. Evopoint Biosciences Inc. · 1 shared drug class
  6. Akeso · 1 shared drug class
  7. Jiangsu ShengDiYa Medicine Co., Ltd. · 1 shared drug class
  8. Air Force Military Medical University, China · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Chengdu Zenitar Biomedical Technology Co., Ltd:

Cite this brief

Drug Landscape (2026). Chengdu Zenitar Biomedical Technology Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chengdu-zenitar-biomedical-technology-co-ltd. Accessed 2026-05-16.

Related